Revvity RVTY Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Segment revenue by Business | ||||||
| Diagnostics | $1.45B+1.7% | $1.42B+2.6% | $1.39B+0.8% | $1.38B+0.8% | $1.37B+0.8% | |
| Life Sciences | $1.45B+1.5% | $1.43B+0.5% | $1.42B+0.3% | $1.42B+1.2% | $1.4B+0.3% | |
| Segment Cost of Revenue by Business | ||||||
| Diagnostics | $655.33M+3.4% | $633.77M+4.8% | $604.46M+2.4% | $590.21M+1.7% | $580.46M+0.7% | |
| Life Sciences | $528.55M+2.4% | $516.3M+1.0% | $510.98M+2.5% | $498.55M+3.0% | $483.95M-0.9% | |
| Segment operating income by Business | ||||||
| Diagnostics | $346.27M+0.6% | $344.17M+0.1% | $343.95M-1.3% | $348.42M-0.9% | $351.75M-0.6% | |
| Life Sciences | $456.53M-0.4% | $458.26M-0.5% | $460.42M-2.0% | $469.94M-0.4% | $472.04M+1.0% | |
| Segment research and development expenses by Business | ||||||
| Diagnostics | $104.52M+0.9% | $103.58M+7.9% | $96.02M+0.5% | $95.52M+4.1% | $91.77M+2.0% | |
| Life Sciences | $115.39M+3.0% | $112.03M+1.4% | $110.5M+1.7% | $108.64M+1.9% | $106.59M+2.1% | |
| Segment Selling, general and administrative expenses by Business | ||||||
| Diagnostics | $343.73M+0.1% | $343.43M-0.5% | $345.07M+0.2% | $344.46M+0.3% | $343.41M+2.2% | |
| Life Sciences | $352.09M+2.2% | $344.52M+0.7% | $341.98M-0.2% | $342.73M+0.8% | $339.91M+0.3% | |
| Foreign currency translation by Business | ||||||
| Diagnostics | $24.59M-49.5% | $48.65M— | —— | —— | —— | |
| Life Sciences | $57M-50.7% | $115.58M+192% | $39.58M-53.7% | $85.57M+972% | $7.99M+117% | |
| Goodwill by Business | ||||||
| Diagnostics | $7.66B-1.0% | $7.73B-0.7% | $7.79B— | —— | —— | |
| Life Sciences | $18.78B+1.0% | $18.61B+1.1% | $18.4B— | —— | —— | |
| Depreciation by Business | ||||||
| Diagnostics | $36.12M+8.1% | $33.4M-5.8% | $35.44M-0.2% | $35.5M+0.8% | $35.22M-2.4% | |
| Life Sciences | $36.21M+8.1% | $33.49M+14.5% | $29.25M-0.7% | $29.47M+1.5% | $29.04M-3.6% | |
| Lease Abandonment Charges Included In Restructuring and Other Costs by Business | ||||||
| Diagnostics | $1.8M+125% | $800K— | —— | —— | —— | |
| Life Sciences | $5.95M-4.0% | $6.2M— | —— | —— | —— | |
| Segment revenue by Geography | ||||||
| Americas | $1.27B+0.9% | $1.26B+0.1% | $1.25B+0.4% | $1.25B+1.3% | $1.23B+0.8% | |
| Asia | $768.85M-0.8% | $775.11M+0.1% | $774.01M-1.3% | $784.42M-0.8% | $790.66M+0.2% | |
| Europe | $866.23M+5.0% | $824.98M+5.1% | $785.25M+2.7% | $764.89M+2.6% | $745.84M+0.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Revvity break its business down?
- Revvity (RVTY) reports segment revenue by business across 2 parts — Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Revvity's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Revvity's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
